Meyka Pro banner
Societal CDMO, Inc.

Societal CDMO, Inc. (NASDAQ: SCTL) Stock Competitors & Peer Comparison

See SCTL's competitors and their performance on the NASDAQ and across the wider stock market.

SCTLNASDAQ
HealthcareDrug Manufacturers - Specialty & Generic
$1.10
$0.01(0.92%)
U.S. Market opens in 64h 6m

Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry

Detailed financial metrics including price, market cap, P/E ratio, and more for SCTL and its NASDAQ peers.

SymbolPriceChange %Market CapP/E RatioEPSDividend Yield
SCTL$1.10+0.92%116.1M-7.86-$0.14N/A
TAK$18.18+0.28%57.9B13.07$1.39+3.47%
HLN$10.00+1.32%44.1B18.66$0.54+1.26%
TEVA$37.34+1.44%43.5B12.74$2.93N/A
VTRS$16.32+1.24%19B6.48$2.52+2.98%
ITCI$131.87+0.00%14B-180.64-$0.73N/A
ELAN$23.97+1.74%12B22.62$1.06N/A
CTLT$63.48+0.00%11.5B-27.84-$2.28N/A
RDY$12.18+0.58%10.2B19.98$0.61+0.69%
LNTH$99.97-0.27%6.5B16.80$5.95N/A
1

Stock Comparison

Select a stock to compare (requires JavaScript). Showing default comparison.

Takeda Pharmaceutical Company Limited (NYSE: TAK)

SCTL vs TAK Comparison August 2026

Societal CDMO, Inc. (NASDAQ: SCTL) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.

Comparing market capitalization, SCTL stands at 116.1M. In comparison, TAK has a market cap of 57.9B. Regarding current trading prices, SCTL is priced at $1.10 on the NASDAQ, while TAK trades at $18.18.

To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.

SCTL currently has a P/E ratio of -7.86, whereas TAK's P/E ratio is 13.07. In terms of profitability, SCTL's ROE is -0.22%, compared to TAK's ROE of +0.02%. Regarding short-term risk, SCTL is less volatile compared to TAK. This indicates lower risk in terms of short-term price fluctuations for SCTL.Check TAK's competition here

Stock price comparison of stocks in the Healthcare Sector

Loading...

Frequently Asked Questions